SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-18-277693
Filing Date
2018-09-19
Accepted
2018-09-19 17:15:58
Documents
7
Period of Report
2018-09-18
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d625073d8k.htm 8-K 21398
2 EXHIBIT 1.1 d625073dex11.htm EX-1.1 218056
3 EXHIBIT 5.1 d625073dex51.htm EX-5.1 9656
4 EXHIBIT 99.1 d625073dex991.htm EX-99.1 7643
5 GRAPHIC g625073dsp49.gif GRAPHIC 3374
6 GRAPHIC g625073dsp50.gif GRAPHIC 5145
7 GRAPHIC g625073dsp51.gif GRAPHIC 4118
  Complete submission text file 0001193125-18-277693.txt   275879
Mailing Address P. O. BOX # 110341 RESEARCH TRIANGLE PARK NC 27709
Business Address 79 T.W. ALEXANDER DRIVE 4501 RESEARCH COMMONS, SUITE 100 RESEARCH TRIANGLE PARK NC 27709 919-213-9835
G1 Therapeutics, Inc. (Filer) CIK: 0001560241 (see all company filings)

IRS No.: 263648180 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38096 | Film No.: 181078232
SIC: 2834 Pharmaceutical Preparations